{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antibody-mediated+Rejection+in+Kidney+Transplant", "query": { "condition": "Antibody-mediated Rejection in Kidney Transplant" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 29, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antibody-mediated+Rejection+in+Kidney+Transplant&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-04T06:36:29.552Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01399593", "title": "Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Antibody Mediated Rejection" ], "interventions": [ { "name": "Eculizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2011-11-02", "completion_date": "2015-11-13", "has_results": true, "last_update_posted_date": "2017-10-03", "last_synced_at": "2026-10-04T06:36:29.552Z", "location_count": 17, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01399593" }, { "nct_id": "NCT01147302", "title": "A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Rejection" ], "interventions": [ { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "C1 Esterase Inhibitor (Human)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2011-08-24", "completion_date": "2013-06-28", "has_results": true, "last_update_posted_date": "2021-06-11", "last_synced_at": "2026-10-04T06:36:29.552Z", "location_count": 4, "location_summary": "Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01147302" }, { "nct_id": "NCT03859388", "title": "Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rejection Chronic Renal", "Kidney Transplant Rejection" ], "interventions": [], "intervention_types": [], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2019-03-01", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2025-04-24", "last_synced_at": "2026-10-04T06:36:29.552Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03859388" }, { "nct_id": "NCT06685757", "title": "A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Antibody-mediated Rejection" ], "interventions": [ { "name": "Felzartamab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 132, "start_date": "2024-12-03", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-10-04T06:36:29.552Z", "location_count": 26, "location_summary": "Los Angeles, California • Orange, California • San Bernardino, California + 20 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Bernardino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06685757" }, { "nct_id": "NCT03380962", "title": "Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kidney Failure, Chronic", "End-Stage Renal Disease", "Transplant Glomerulopathy", "Transplant;Failure,Kidney", "Kidney Transplant Failure and Rejection", "Antibody-mediated Rejection", "Kidney Transplant; Complications" ], "interventions": [ { "name": "Clazakizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanley Jordan, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "15 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2018-02-27", "completion_date": "2025-08-30", "has_results": false, "last_update_posted_date": "2025-03-24", "last_synced_at": "2026-10-04T06:36:29.552Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03380962" }, { "nct_id": "NCT05156710", "title": "BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Transplant Rejection" ], "interventions": [ { "name": "BIVV020 (SAR445088)", "type": "DRUG" }, { "name": "Intravenous immunoglobulin (IVIg)", "type": "DRUG" }, { "name": "Rituximab or biosimilar", "type": "DRUG" }, { "name": "Antithymocyte globulin (ATG)", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2022-06-09", "completion_date": "2026-10-20", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-04T06:36:29.552Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05156710" }, { "nct_id": "NCT04046549", "title": "A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Allografts", "Rejection; Transplant, Kidney", "Transplant Rejection", "Kidney Transplantation" ], "interventions": [ { "name": "Belatacept", "type": "DRUG" }, { "name": "VIB4920", "type": "DRUG" }, { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 25, "start_date": "2019-10-30", "completion_date": "2023-03-22", "has_results": true, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-10-04T06:36:29.552Z", "location_count": 4, "location_summary": "Los Angeles, California • San Francisco, California • Durham, North Carolina + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04046549" }, { "nct_id": "NCT05452317", "title": "Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Antibody-mediated Rejection in Kidney Transplant" ], "interventions": [ { "name": "Chronic active AMR group", "type": "OTHER" }, { "name": "Non-Chronic active AMR group", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "CSL Behring", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2022-07-14", "completion_date": "2023-04-04", "has_results": false, "last_update_posted_date": "2023-04-13", "last_synced_at": "2026-10-04T06:36:29.552Z", "location_count": 3, "location_summary": "Los Angeles, California • Baltimore, Maryland • St Louis, Missouri", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05452317" }, { "nct_id": "NCT03897205", "title": "An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplant Rejection" ], "interventions": [ { "name": "Imlifidase", "type": "DRUG" }, { "name": "Plasma Exchange", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hansa Biopharma AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2019-04-30", "completion_date": "2022-11-16", "has_results": true, "last_update_posted_date": "2024-02-28", "last_synced_at": "2026-10-04T06:36:29.552Z", "location_count": 4, "location_summary": "Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03897205" }, { "nct_id": "NCT05456243", "title": "Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kidney Transplant" ], "interventions": [ { "name": "Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)", "type": "BIOLOGICAL" }, { "name": "High dose adipose tissue derived mesenchymal stromal cells (A-MSC)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 8, "start_date": "2023-01-30", "completion_date": "2026-04-20", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-04T06:36:29.552Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05456243" } ] }